Eli Lilly & Co. (LLY)

86.28
0.54 0.62
NYSE : Health Technology
Prev Close 86.82
Open 86.74
Day Low/High 86.20 / 87.16
52 Wk Low/High 73.69 / 89.09
Volume 4.66M
Avg Volume 3.83M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 93.47B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (2.49%)

Latest News

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.

Jim's Daily Rundown

Jim discusses news on Qualcomm-NXP Semiconductors, why we would sell Constellation today, and mentions Raytheon, Eli Lilly, PepsiCo, Honeywell and Emerson Electric!

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

The biopharmaceutical companies saw their stocks drop amid fallout of failed Alzheimer's drug trials.

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks finished mixed on Tuesday, following the summit between Donald Trump and North Korean leader Kim Jong Un and as Wall Street turns its attention the start of the Federal Reserve's two-day meeting.

Jim's Daily Rundown

Jim discusses our Salesforce buy, Eli Lilly, UnitedHealth and Cimarex and also answers a club member's question!

Peace Hopes Weigh on Defense Stocks

Shares of defense stocks slide after Trump meets Kim.

Trump Meets Kim, AT&T and Time Warner, McDonald's - 5 Things You Must Know

Trump Meets Kim, AT&T and Time Warner, McDonald's - 5 Things You Must Know

U.S. stock futures trade lower after a signed agreement between Donald Trump and North Korean leader Kim Jong Un offers few specifics on denuclearization of the Korean peninsula; a ruling on the AT&T and Time Warner merger is expected Tuesday; McDonald's reportedly to detail its restructuring plan.

Update On Phase 3 Clinical Trials Of Lanabecestat For Alzheimer's Disease

Update On Phase 3 Clinical Trials Of Lanabecestat For Alzheimer's Disease

Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.

Jim's Daily Rundown

Jim discusses a Cimarex upgrade, Eli Lilly receiving positive attention, Microsoft and gaming, Facebook, and answers a club member's question on PepsiCo!

Elanco Animal Health Introduces New Respiratory PRRS Vaccine

Elanco Animal Health Introduces New Respiratory PRRS Vaccine

Manufacturer gives swine producers a new tool to combat the devastating disease

Lilly To Unveil New Data At The Annual European Congress Of Rheumatology, Furthering Commitment To Scientific Discovery In Immunology

Lilly To Unveil New Data At The Annual European Congress Of Rheumatology, Furthering Commitment To Scientific Discovery In Immunology

Highlights include new Phase 2 data for baricitinib in systemic lupus erythematosus

Weekly Roundup

Markets bathed in the afterglow of the strong jobs report for most of the week.

Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer By TRC Capital Corp.

Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer By TRC Capital Corp.

INDIANAPOLIS, June 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has learned of an unsolicited mini-tender offer by TRC Capital Corp.

Jim's Daily Rundown

Jim discusses Constellation Brands, Goldman Sachs and a new position in Salesforce.com.

DDW 2018: Patients With Moderate-to-Severe Ulcerative Colitis Achieved Clinical And Endoscopic Remission With Mirikizumab In Phase 2 Trial

DDW 2018: Patients With Moderate-to-Severe Ulcerative Colitis Achieved Clinical And Endoscopic Remission With Mirikizumab In Phase 2 Trial

- New data are the first safety and efficacy data for an IL-23p19 monoclonal antibody for the treatment of moderate-to-severe ulcerative colitis -

Trimming Eli Lilly

We'll book a small profit off recent strength as we rebuild our cash position.

Weekly Roundup

Markets go through a short and volatile week.

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets For The Treatment Of Adults With Moderately-to-Severely Active Rheumatoid Arthritis

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets For The Treatment Of Adults With Moderately-to-Severely Active Rheumatoid Arthritis

The approval of OLUMIANT is based on the Phase 3 clinical trial program that demonstrated efficacy for difficult to treat patients1

Jim's Daily Rundown

Jim talks about Friday's jobs report, Nucor, the recent decline in Micron, 3M, WestRock, and answers a club member's question about DowDuPont!

Lilly To Showcase New Data At Digestive Disease Week 2018 For Mirikizumab In Moderate-to-Severe Ulcerative Colitis

Lilly To Showcase New Data At Digestive Disease Week 2018 For Mirikizumab In Moderate-to-Severe Ulcerative Colitis

INDIANAPOLIS, June 1, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced that it will present new data evaluating mirikizumab for the treatment of moderate-to-severe ulcerative colitis (UC) at Digestive Disease Week (DDW), taking place June...

Lilly To Participate In Goldman Sachs Global Healthcare Conference

INDIANAPOLIS, May 31, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018.

Weekly Roundup

China trade wars, North Korea tensions and oil volatility hit the markets this week.

12 Stocks That Our Writers and Their Sources Recommend You Buy Here

12 Stocks That Our Writers and Their Sources Recommend You Buy Here

From Netflix to Kraft Heinz, these names look good.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

Sue Mahony To Retire As President Of Lilly Oncology

Mahony will continue in position through August 31, successor named at a later date

TheStreet Quant Rating: C+ (Hold)